<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Respir Res</journal-id><journal-title>Respiratory Research</journal-title><issn pub-type="ppub">1465-9921</issn><issn pub-type="epub">1465-993X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1465-9921-10-73</article-id><article-id pub-id-type="pmid">19671143</article-id><article-id pub-id-type="doi">10.1186/1465-9921-10-73</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Level and course of FEV<sub>1 </sub>in relation to polymorphisms in <italic>NFE2L2 </italic>and <italic>KEAP1 </italic>in the general population</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Siedlinski</surname><given-names>Mateusz</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>m.siedlinski@epi.umcg.nl</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Postma</surname><given-names>Dirkje S</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>d.s.postma@int.umcg.nl</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Boer</surname><given-names>Jolanda MA</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>jolanda.boer@rivm.nl</email></contrib><contrib id="A4" contrib-type="author"><name><surname>van der Steege</surname><given-names>Gerrit</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>gerrit.vandersteege@wur.nl</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Schouten</surname><given-names>Jan P</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>j.p.schouten@epi.umcg.nl</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Smit</surname><given-names>Henriette A</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>jet.smit@rivm.nl</email></contrib><contrib id="A7" corresp="yes" contrib-type="author"><name><surname>Boezen</surname><given-names>H Marike</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>h.m.boezen@epi.umcg.nl</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands</aff><aff id="I2"><label>2</label>Department of Pulmonology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands</aff><aff id="I3"><label>3</label>National Institute for Public Health and the Environment, Bilthoven, The Netherlands</aff><aff id="I4"><label>4</label>Department of Medical Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands</aff><pub-date pub-type="ppub"><year>2009</year></pub-date><pub-date pub-type="epub"><day>11</day><month>8</month><year>2009</year></pub-date><volume>10</volume><issue>1</issue><fpage>73</fpage><lpage>73</lpage><ext-link ext-link-type="uri" xlink:href="http://respiratory-research.com/content/10/1/73"/><history><date date-type="received"><day>31</day><month>3</month><year>2009</year></date><date date-type="accepted"><day>11</day><month>8</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Siedlinski et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Siedlinski et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Siedlinski Mateusz m.siedlinski@epi.umcg.nl </dc:author><dc:title> Level and course of FEV1 in relation to polymorphisms in NFE2L2 and KEAP1 in the general population </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Respiratory Research 10(1): 73-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1465-9921(2009)10:1&#x0003c;73&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1465-9921</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>The metabolism of xenobiotics plays an essential role in smoking related lung function loss and development of Chronic Obstructive Pulmonary Disease. Nuclear Factor Erythroid 2-Like 2 (NFE2L2 or NRF2) and its cytosolic repressor Kelch-like ECH-associated protein-1 (KEAP1) regulate transcription of enzymes involved in cellular detoxification processes and <italic>Nfe2l2</italic>-deficient mice develop tobacco-induced emphysema. We assessed the impact of Single Nucleotide Polymorphisms (SNPs) in both genes on the level and longitudinal course of Forced Expiratory Volume in 1 second (FEV<sub>1</sub>) in the general population.</p></sec><sec sec-type="methods"><title>Methods</title><p>Five <italic>NFE2L2 </italic>and three <italic>KEAP1 </italic>tagging SNPs were genotyped in the population-based Doetinchem cohort (n = 1,152) and the independent Vlagtwedde-Vlaardingen cohort (n = 1,390). On average 3 FEV<sub>1 </sub>measurements during 3 surveys, respectively 7 FEV<sub>1 </sub>measurements during 8 surveys were present. Linear Mixed Effect models were used to test cross-sectional and longitudinal genetic effects on repeated FEV<sub>1 </sub>measurements.</p></sec><sec><title>Results</title><p>In the Vlagtwedde-Vlaardingen cohort SNP rs11085735 in <italic>KEAP1 </italic>was associated with a higher FEV<sub>1 </sub>level (p = 0.02 for an additive effect), and SNP rs2364723 in <italic>NFE2L2 </italic>was associated with a lower FEV<sub>1 </sub>level (p = 0.06). The associations were even more significant in the pooled cohort analysis. No significant association of <italic>KEAP1 </italic>or <italic>NFE2L2 </italic>SNPs with FEV<sub>1 </sub>decline was observed.</p></sec><sec><title>Conclusion</title><p>This is the first genetic study on variations in key antioxidant transcriptional regulators <italic>KEAP1 </italic>and <italic>NFE2L2 </italic>and lung function in a general population. It identified 2 SNPs in <italic>NFE2L2 </italic>and <italic>KEAP1 </italic>which affect the level of FEV<sub>1 </sub>in the general population. It additionally shows that <italic>NFE2L2 </italic>and <italic>KEAP1 </italic>variations are unlikely to play a role in the longitudinal course of FEV<sub>1 </sub>in the general population.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>The mortality and morbidity of Chronic Obstructive Pulmonary Disease (COPD) has been increasing over the past decades and the disease is a fundamental medical and economical problem in Western societies [<xref ref-type="bibr" rid="B1">1</xref>]. A genetic predisposition is thought to play a crucial role in the onset of COPD and the heritability of lung function loss that precedes COPD development has been clearly established [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. Several polymorphisms have been identified in association with level of lung function, but subsequent studies have failed to replicate these reported associations [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. So far, only a small subset of polymorphisms has been consistently replicated in their association with COPD development or lung function decline across independent studies or populations [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B11">11</xref>].</p><p>Nuclear Factor (Erythroid-derived 2)-Like 2 (NFE2L2 or NRF2) regulates the transcription of numerous antioxidant enzymes in response to oxidant injury, via direct binding to the antioxidant responsive element in the target gene [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B15">15</xref>]. It therefore is a potent candidate gene for excess lung function loss and COPD development.</p><p>Kelch-like ECH-associated protein-1 (KEAP1) is a cytosolic repressor of NFE2L2. Oxidative stress causes disruption of the KEAP1-NFE2L2 complex, translocation of NFE2L2 to the nucleus and subsequent induction of the expression of antioxidant genes [<xref ref-type="bibr" rid="B16">16</xref>]. It has been shown that <italic>Nfe2l2 </italic>protects mice against elastase-induced [<xref ref-type="bibr" rid="B17">17</xref>] and tobacco-induced [<xref ref-type="bibr" rid="B18">18</xref>] emphysema. Additionally, the expression pattern of both <italic>KEAP1 </italic>and <italic>NFE2L2 </italic>is different in COPD patients as compared to healthy never- or former- smokers [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>] and the expression of NFE2L2-regulated antioxidant genes is lower in COPD subjects than in non-diseased controls [<xref ref-type="bibr" rid="B21">21</xref>]. Three new polymorphisms have been discovered in the promoter region of <italic>NFE2L2</italic>, but these were not associated with COPD in a Japanese population [<xref ref-type="bibr" rid="B22">22</xref>]. One study showed that one of these polymorphisms decreases <italic>NFE2L2 </italic>expression <italic>in vitro </italic>and is associated with development of acute lung injury in a Caucasian population [<xref ref-type="bibr" rid="B23">23</xref>]. So far no studies have investigated the role of <italic>NFE2L2 </italic>or <italic>KEAP1 </italic>polymorphisms in relation to the longitudinal course of lung function in the general population.</p><p>Therefore, in the current study we investigated whether <italic>NFE2L2 </italic>or <italic>KEAP1 </italic>polymorphisms affect the level and longitudinal course of FEV<sub>1 </sub>(Forced Expiratory Volume in 1 second), both being important risks for COPD [<xref ref-type="bibr" rid="B24">24</xref>]. In order to assure consistency of results, we performed this study in two prospective and independent population-based cohorts.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Subjects</title><p>Subjects from the Doetinchem cohort study [<xref ref-type="bibr" rid="B25">25</xref>], a prospective part of the MORGEN study [<xref ref-type="bibr" rid="B26">26</xref>], were included. A sub-sample (n = 1,152 subjects with 3,115 FEV<sub>1 </sub>measurements during 3 surveys: surveys 1993&#x02013;1997 (n = 1,152), 1998&#x02013;2002 (n = 1,152), and 2003&#x02013;2007 (n = 811)), table <xref ref-type="table" rid="T1">1</xref>) was randomly selected from the total cohort with spirometry tests and DNA available as described previously [<xref ref-type="bibr" rid="B27">27</xref>]. FEV<sub>1 </sub>was measured three times (maneuver performed with a heated pneumotachograph (Jaeger, Germany)) with 5-year intervals according to the European Respiratory Society (ERS) guidelines [<xref ref-type="bibr" rid="B28">28</xref>].</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Characteristics of Doetinchem cohort and Vlagtwedde-Vlaardingen cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><bold>Doetinchem cohort</bold><break/>(n = 1,152)</td><td align="center"><bold>Vlagtwedde-Vlaardingen cohort</bold><break/>(n = 1,390)</td></tr></thead><tbody><tr><td align="left"><bold>Total duration of follow-up </bold>(years)</td><td align="center">10</td><td align="center">25</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Number of visits </bold>(median)</td><td align="center">3</td><td align="center">7</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>The total number of FEV<sub>1 </sub>measurements across all visits</bold></td><td align="center">3,115</td><td align="center">8,159</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Follow-up time frame</bold>, years</td><td align="center">1997&#x02013;2007</td><td align="center">1965&#x02013;1990</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Males</bold>, n (%)</td><td align="center">541 (47.0)</td><td align="center">714 (51.4)</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>FEV<sub>1 </sub>change in ml/year</bold>, mean (SD)</td><td align="center">-26.2 (33.4)</td><td align="center">-20.8 (22.9)</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Last available:</bold></td><td></td><td></td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>FEV<sub>1 </sub>level in liters</bold>, mean (SD)</td><td align="center">3.31 (0.80)</td><td align="center">2.86 (0.77)</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Age in years</bold>, median (range)</td><td align="center">53.7 (32&#x02013;76)</td><td align="center">52.0 (35&#x02013;79)</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Never smokers</bold>, n (%)</td><td align="center">372 (32.3)</td><td align="center">445 (32.0)</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Packyears smoked in ever smokers</bold>, median (range)</td><td align="center">13.2 (0.004&#x02013;84.0)</td><td align="center">18.9 (0.1&#x02013;262.2)</td></tr></tbody></table><table-wrap-foot><p>FEV<sub>1 </sub>= Forced Expiratory Volume in 1 second</p><p>SD = Standard Deviation</p></table-wrap-foot></table-wrap><p>An independent cohort (Vlagtwedde-Vlaardingen; n = 1,390 subjects with 8,159 FEV<sub>1 </sub>measurements during 8 surveys, table <xref ref-type="table" rid="T1">1</xref>) was additionally studied. This cohort was prospectively followed for 25 years with FEV<sub>1 </sub>measurements (maneuver performed with a water-sealed spirometer (Lode Instruments, the Netherlands)) every 3 years (following ERS guidelines) [<xref ref-type="bibr" rid="B29">29</xref>].</p><p>The study protocols were approved by local medical ethics committees and all participants gave their written informed consent.</p></sec><sec><title>Selection/genotyping of Single Nucleotide Polymorphisms (SNPs)</title><p>We pairwise tagged <italic>NFE2L2 </italic>and <italic>KEAP1 </italic>with respectively five and three SNPs according to the HapMap CEU genotype data (23a) with an r<sup>2 </sup>threshold of 0.8 and Minor Allele Frequency (MAF)&#x0003e;5%. We additionally included three novel <italic>NFE2L2 </italic>polymorphisms [<xref ref-type="bibr" rid="B22">22</xref>] with MAF&#x0003e;5%: G(-686)A (rs35652124), C(-650)A (rs6721961) and Trinucleotide CCG Repeat (TNR). SNPs were genotyped by K-Bioscience Ltd (UK) using their patent-protected competitive allele specific PCR system (KASPar). The additional file <xref ref-type="supplementary-material" rid="S1">1</xref> contains details on SNP-selection and <italic>NFE2L2 </italic>TNR genotyping.</p></sec><sec><title>Statistics</title><sec><title>SNPs in NFE2L2 and KEAP1 and level of FEV<sub>1</sub></title><p>We used Linear Mixed Effect (LME) to study the effects of SNPs and haplotypes (additive genetic model; coded: 0 = homozygote wild type, 1 = heterozygote, 2 = homozygote mutant) on the level of FEV<sub>1 </sub>in both cohorts separately, using all available FEV<sub>1 </sub>measurements across all surveys. This analysis was adjusted for age (defined with natural cubic spline with 4 degrees of freedom in order to take into account varying effects of age on the level of FEV<sub>1 </sub>throughout lifetime), sex, packyears smoked, height and the correlation of FEV<sub>1 </sub>measurements within each subject (random effect assigned to the intercept).</p></sec><sec><title>SNPs in NFE2L2 and KEAP1 and course of FEV<sub>1</sub></title><p>We studied the effect of SNPs on course of FEV<sub>1 </sub>by introducing the interaction term of SNP &#x000d7; time (defined in relation to the first FEV<sub>1 </sub>measurement and with random effect assigned) into the primary analysis model described above (see additional file <xref ref-type="supplementary-material" rid="S1">1</xref> for details).</p></sec><sec><title>Analysis on the pooled cohorts</title><p>Finally, we pooled both cohorts, and performed analysis on the level and course of FEV<sub>1 </sub>with additional adjustment for cohort. We studied also two other models (recessive/dominant = mutant/wild type homozygotes compared to the rest genotypes) which were reported in case they showed significant effects in the pooled cohort analysis. Similarly we investigated whether there was a significant interaction between <italic>KEAP1 </italic>and <italic>NFE2L2 </italic>genotypes in relation to the level of FEV<sub>1</sub>, using two-way combinations of genetic effects with the highest statistical power i.e. dominant and additive.</p></sec><sec><title>Interaction with smoking</title><p>Gene by smoking interaction analysis in relation to the level of FEV<sub>1 </sub>was performed on the pooled cohorts using data from single surveys (i.e. second in the Doetinchem cohort and last in the Vlagtwedde-Vlaardingen cohort) in order to ensure the highest cumulative exposure to tobacco smoke and the highest number of subjects analyzed. The following interaction terms in two following regression models were analyzed:</p><p>1. SNP by ever/never smoking status in the total population with adjustment for ever-smoking status and genotypes and no adjustment for packyears smoked</p><p>2. SNP by packyears smoked within ever smokers with adjustment for packyears smoked and genotypes</p><p>P values &#x0003c; 0.05 were considered to be statistically significant (tested 2-sided).</p></sec></sec><sec><title>Software</title><p>LME models were run using S-PLUS (version 7.0). Linkage Disequilibrium (LD) plots and Hardy-Weinberg Equilibrium (HWE) tests were performed with Haploview (version 4.1) [<xref ref-type="bibr" rid="B30">30</xref>]. We identified, with a probability &#x0003e; 95%, subjects carrying no, one or two copies of a specific haplotype, using the *. out_pairs output file from PHASE software (version 2.1) [<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>]. We used MIX software (version 1.7) [<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B34">34</xref>] to meta-analyze results from the Doetinchem, Vlagtwedde-Vlaardingen and British 1958 Birth cohort [<xref ref-type="bibr" rid="B35">35</xref>].</p></sec></sec><sec><title>Results</title><sec><title>Genetic structure of <italic>NFE2L2 </italic>and <italic>KEAP1</italic></title><p>There was an excess of <italic>KEAP1 </italic>rs1048290 SNP heterozygotes in the Vlagtwedde-Vlaardingen cohort, which caused a significant deviation (p = 0.01) from HWE (table <xref ref-type="table" rid="T2">2</xref>). To eliminate potential genotyping errors as underlying cause of this, we additionally genotyped <italic>KEAP1 </italic>rs9676881 SNP, that is in complete LD with rs1048290 (based on HapMap; distance between the two SNPs = 3.7 kb). This SNP also showed a significant deviation from HWE (p = 0.01; frequency of 50.6% and 12.4% for heterozygotes and homozygote mutants respectively) in the Vlagtwedde-Vlaardingen cohort.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Characteristics of <italic>NFE2L2 </italic>and <italic>KEAP1 </italic>genotypes in the Doetinchem cohort and Vlagtwedde-Vlaardingen cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td></td><td align="center" colspan="4"><bold>Doetinchem cohort</bold><break/>(n = 1,152)</td><td align="center" colspan="4"><bold>Vlagtwedde-Vlaardingen cohort</bold><break/>(n = 1,390)</td></tr></thead><tbody><tr><td align="center" colspan="2"><bold>The total SNP call rate</bold>, %</td><td align="center" colspan="4">97.5</td><td align="center" colspan="4">96.4</td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="center" colspan="2"><bold>The total unique haplotype call rate</bold>, %</td><td align="center" colspan="4">93.7</td><td align="center" colspan="4">90.6</td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="center" colspan="2"><bold>Genotypes distribution</bold>, n(%):</td><td align="center">Heterozygotes</td><td align="center">Homozygotes mutant</td><td align="center">MAF</td><td align="center">HWE p value</td><td align="center">Heterozygotes</td><td align="center">Homozygotes mutant</td><td align="center">MAF</td><td align="center">HWE p value</td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left"><italic>NFE2L2</italic></td><td align="left">rs6726395</td><td align="center">561 (49.6)</td><td align="center">256 (22.7)</td><td align="center">47.5</td><td align="center">0.91</td><td align="center">670 (49.6)</td><td align="center">277 (20.5)</td><td align="center">45.3</td><td align="center">0.82</td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td></td><td align="left">rs4243387</td><td align="center">210 (18.8)</td><td align="center">10 (0.9)</td><td align="center">10.3</td><td align="center">0.69</td><td align="center">191 (14.1)</td><td align="center">14 (1.0)</td><td align="center">8.1</td><td align="center">0.07</td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td></td><td align="left">rs1806649</td><td align="center">454 (40.5)</td><td align="center">72 (6.4)</td><td align="center">26.7</td><td align="center">0.27</td><td align="center">510 (39.1)</td><td align="center">83 (6.4)</td><td align="center">25.9</td><td align="center">0.55</td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td></td><td align="left">rs13001694</td><td align="center">530 (47.3)</td><td align="center">178 (15.9)</td><td align="center">39.6</td><td align="center">0.74</td><td align="center">647 (48.1)</td><td align="center">223 (16.6)</td><td align="center">40.6</td><td align="center">0.82</td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td></td><td align="left">rs2364723</td><td align="center">499 (44.6)</td><td align="center">105 (9.4)</td><td align="center">31.7</td><td align="center">0.38</td><td align="center">574 (42.8)</td><td align="center">156 (11.6)</td><td align="center">33.0</td><td align="center">0.42</td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td></td><td align="left">HaplotypeC</td><td align="center">326 (30.4)</td><td align="center">41 3.8)</td><td align="center">18.9</td><td align="center">0.72</td><td align="center">402 (32.6)</td><td align="center">44 (3.6)</td><td align="center">19.1</td><td align="center">0.42</td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td></td><td align="left">HaplotypeD</td><td align="center">237 (22.1)</td><td align="center">13 1.2)</td><td align="center">12.4</td><td align="center">0.47</td><td align="center">283 (22.9)</td><td align="center">14 (1.1)</td><td align="center">13.0</td><td align="center">0.13</td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left"><italic>KEAP1</italic></td><td align="left">rs1048290</td><td align="center">507 (45.5)</td><td align="center">147 (13.2)</td><td align="center">36.0</td><td align="center">0.77</td><td align="center">671 (50.6)</td><td align="center">164 (12.4)</td><td align="center">37.6</td><td align="center">0.01</td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td></td><td align="left">rs11085735</td><td align="center">117 (10.4)</td><td align="center">5 (0.4)</td><td align="center">5.6</td><td align="center">0.56</td><td align="center">129 (9.6)</td><td align="center">2 (0.1)</td><td align="center">4.9</td><td align="center">0.77</td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td></td><td align="left">rs1048287</td><td align="center">203 (18.0)</td><td align="center">18 (1.6)</td><td align="center">10.6</td><td align="center">0.14</td><td align="center">248 (18.4)</td><td align="center">11 (0.8)</td><td align="center">10.0</td><td align="center">0.51</td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td></td><td align="left">HaplotypeA</td><td align="center">520 (47.9)</td><td align="center">197 (18.1)</td><td align="center">57.7</td><td align="center">0.64</td><td align="center">659 (51.2)</td><td align="center">222 (17.3)</td><td align="center">57.0</td><td align="center">0.13</td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td></td><td align="left">HaplotypeB</td><td align="center">401 (36.9)</td><td align="center">80 (7.4)</td><td align="center">26.1</td><td align="center">0.27</td><td align="center">541 (42.1)</td><td align="center">88 (6.8)</td><td align="center">28.0</td><td align="center">0.14</td></tr></tbody></table><table-wrap-foot><p>SNP = Single Nucleotide Polymorphism</p><p>HWE = Hardy Weinberg Equilibrium</p><p>MAF = Minor Allele Frequency</p><p>NFE2L2 = Nuclear Factor (Erythroid-derived 2)-Like 2</p><p>KEAP1 = Kelch-like ECH-associated protein-1</p></table-wrap-foot></table-wrap><p>Five <italic>NFE2L2 </italic>TNR alleles, including three alleles not observed previously [<xref ref-type="bibr" rid="B22">22</xref>] i.e. 2, 6 and 7 CCG repeats, were identified in the Doetinchem cohort. These three novel alleles occurred with a total cumulative frequency of 0.4% (see additional file <xref ref-type="supplementary-material" rid="S1">1</xref> for details).</p><p>The <italic>NFE2L2 </italic>G(-686)A (rs35652124) SNP, CCG TNR and rs2364723 SNP were in high LD as well as <italic>NFE2L2 </italic>C(-650)A (rs6721961) and rs4243387 SNPs (r<sup>2 </sup>&#x02265; 0.96, figure <xref ref-type="fig" rid="F1">1</xref>). We observed 5 prevalent (&#x0003e;5% frequency) haplotypes in <italic>NFE2L2</italic>, and 4 prevalent haplotypes in <italic>KEAP1 </italic>in both cohorts (table <xref ref-type="table" rid="T3">3</xref>). Two haplotypes in <italic>NFE2L2 </italic>(haplotypes C and D) were unique, i.e. they were not tagged by a single allele of any SNP (table <xref ref-type="table" rid="T3">3</xref>). Similarly, 2 haplotypes in <italic>KEAP1 </italic>(haplotypes A and B) were unique (table <xref ref-type="table" rid="T3">3</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Characteristics of <italic>NFE2L2 </italic>and <italic>KEAP1 </italic>haplotypes occurring with &#x0003e;5% frequency in the two cohorts studied</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Gene</bold></td><td align="center"><bold>Haplotype</bold></td><td align="center"><bold>SNP*</bold></td><td align="center" colspan="2"><bold>Frequency [%]</bold></td></tr><tr><td></td><td></td><td colspan="3"><hr></hr></td></tr><tr><td></td><td></td><td align="center">rs6726395-rs4243387-rs1806649- rs13001694-rs2364723</td><td align="center"><bold>Doetinchem cohort</bold></td><td align="center"><bold>Vlagtwedde-Vlaardingen cohort</bold></td></tr></thead><tbody><tr><td align="center"><italic>NFE2L2</italic></td><td align="center">A</td><td align="center">0-0-0-0-1</td><td align="center">31.0</td><td align="center">32.5</td></tr><tr><td></td><td colspan="4"><hr></hr></td></tr><tr><td></td><td align="center">B</td><td align="center">1-0-1-1-0</td><td align="center">25.0</td><td align="center">24.5</td></tr><tr><td></td><td colspan="4"><hr></hr></td></tr><tr><td></td><td align="center">C</td><td align="center">0-0-0-0-0</td><td align="center">18.9</td><td align="center">19.1</td></tr><tr><td></td><td colspan="4"><hr></hr></td></tr><tr><td></td><td align="center">D</td><td align="center">1-0-0-1-0</td><td align="center">12.4</td><td align="center">13.0</td></tr><tr><td></td><td colspan="4"><hr></hr></td></tr><tr><td></td><td align="center">E</td><td align="center">1-1-0-0-0</td><td align="center">9.3</td><td align="center">7.0</td></tr><tr><td></td><td colspan="4"><hr></hr></td></tr><tr><td></td><td align="center">-</td><td align="center">Rare pooled</td><td align="center">3.6</td><td align="center">3.9</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td></td><td></td><td align="center">rs1048290-rs11085735-rs1048287</td><td></td><td></td></tr><tr><td></td><td colspan="4"><hr></hr></td></tr><tr><td align="center"><italic>KEAP1</italic></td><td align="center">A</td><td align="center">0-0-0</td><td align="center">57.7</td><td align="center">57.0</td></tr><tr><td></td><td colspan="4"><hr></hr></td></tr><tr><td></td><td align="center">B</td><td align="center">1-0-0</td><td align="center">26.1</td><td align="center">28.0</td></tr><tr><td></td><td colspan="4"><hr></hr></td></tr><tr><td></td><td align="center">C</td><td align="center">1-0-1</td><td align="center">9.8</td><td align="center">9.7</td></tr><tr><td></td><td colspan="4"><hr></hr></td></tr><tr><td></td><td align="center">D</td><td align="center">0-1-0</td><td align="center">5.5</td><td align="center">4.9</td></tr><tr><td></td><td colspan="4"><hr></hr></td></tr><tr><td></td><td align="center">-</td><td align="center">Rare pooled</td><td align="center">0.9</td><td align="center">0.4</td></tr></tbody></table><table-wrap-foot><p>*0/1 corresponds to the major/minor allele of SNPs</p><p>NFE2L2 = Nuclear Factor (Erythroid-derived 2)-Like 2</p><p><italic>KEAP1 = Kelch-like ECH-associated protein-1</italic>.</p></table-wrap-foot></table-wrap><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold><italic>NFE2L2 </italic>and <italic>KEAP1 </italic>linkage disequilibrium plots (100&#x000b7;r<sup>2</sup>) in the Doetinchem cohort (n = 1,152)</bold>. *given for the wild type (5 CCG repeats) and the mutant (4 CCG repeats) allele <italic>NFE2L2 </italic>= <italic>Nuclear Factor Erythroid 2-Like 2 KEAP1 = Kelch-like ECH-associated protein-1</italic>.</p></caption><graphic xlink:href="1465-9921-10-73-1"/></fig></sec><sec><title><italic>NFE2L2 </italic>and <italic>KEAP1 </italic>variations and level of FEV<sub>1</sub></title><p>SNP rs2364723 in <italic>NFE2L2 </italic>was associated (p = 0.06) with a lower FEV<sub>1 </sub>level, and SNP rs11085735 in <italic>KEAP1 </italic>was significantly associated with a higher FEV<sub>1 </sub>level in the Vlagtwedde-Vlaardingen cohort (table <xref ref-type="table" rid="T4">4</xref>). Similar, but non-significant trends for an additive effect were observed in the Doetinchem cohort, resulting in significant effects in the pooled cohort analysis (table <xref ref-type="table" rid="T4">4</xref>).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Additive effects of genetic variations in <italic>NFE2L2 </italic>and <italic>KEAP1 </italic>on the level of FEV<sub>1</sub></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Gene</bold></td><td align="left"><bold>Variation</bold></td><td align="center" colspan="3"><bold>Doetinchem cohort</bold></td><td align="center" colspan="3"><bold>Vlagtwedde-Vlaardingen cohort</bold></td><td align="center"><bold>Pooled cohorts</bold></td></tr><tr><td></td><td></td><td colspan="7"><hr></hr></td></tr><tr><td></td><td></td><td align="center"><bold>B [ml]</bold></td><td align="center"><bold>95% CI</bold></td><td align="center"><bold>p</bold></td><td align="center"><bold>B [ml]</bold></td><td align="center"><bold>95% CI</bold></td><td align="center"><bold>p</bold></td><td align="center"><bold>p</bold></td></tr></thead><tbody><tr><td align="left"><italic>NFE2L2</italic></td><td align="left">rs6726395</td><td align="center">-13.8</td><td align="center">-51.0 &#x02013; 23.4</td><td align="center">0.47</td><td align="center">14.1</td><td align="center">-17.9 &#x02013; 46.1</td><td align="center">0.39</td><td align="center">0.827</td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">rs4243387</td><td align="center">0.2</td><td align="center">-61.9 &#x02013; 62.3</td><td align="center">0.99</td><td align="center">20.6</td><td align="center">-36.5 &#x02013; 77.7</td><td align="center">0.48</td><td align="center">0.620</td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">rs1806649</td><td align="center">-44.5</td><td align="center">-87.3 &#x02013; -1.7</td><td align="center"><bold>0.04</bold></td><td align="center">0.2</td><td align="center">-36.7 &#x02013; 37.1</td><td align="center">0.99</td><td align="center">0.150</td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">rs13001694</td><td align="center">-20.9</td><td align="center">-58.7 &#x02013; 16.9</td><td align="center">0.28</td><td align="center">13.0</td><td align="center">-19.5 &#x02013; 45.5</td><td align="center">0.43</td><td align="center">0.948</td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">rs2364723</td><td align="center">-22.9</td><td align="center">-63.6 &#x02013; 17.8</td><td align="center">0.27</td><td align="center">-32.1</td><td align="center">-65.4 &#x02013; 1.2</td><td align="center">0.06</td><td align="center"><bold>0.026</bold></td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">Haplotype C</td><td align="center">44.8</td><td align="center">-3.4 &#x02013; 93.0</td><td align="center">0.07</td><td align="center">24.3</td><td align="center">-17.8 &#x02013; 66.4</td><td align="center">0.26</td><td align="center"><bold>0.040</bold></td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">Haplotype D</td><td align="center">47.0</td><td align="center">-12.1 &#x02013; 106.1</td><td align="center">0.11</td><td align="center">21.2</td><td align="center">-29.7 &#x02013; 72.1</td><td align="center">0.41</td><td align="center">0.064</td></tr><tr><td colspan="9"><hr></hr></td></tr><tr><td align="left"><italic>KEAP1</italic></td><td align="left">rs1048290</td><td align="center">12.4</td><td align="center">-26.3 &#x02013; 51.1</td><td align="center">0.53</td><td align="center">-6.5</td><td align="center">-40.8 &#x02013; 27.8</td><td align="center">0.71</td><td align="center">0.784</td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">rs11085735</td><td align="center">69.9</td><td align="center">-9.3 &#x02013; 149.1</td><td align="center">0.08</td><td align="center">97.1</td><td align="center">22.4 &#x02013; 171.8</td><td align="center"><bold>0.01</bold></td><td align="center"><bold>0.003</bold></td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">rs1048287</td><td align="center">-11.9</td><td align="center">-70.8 &#x02013; 47.0</td><td align="center">0.69</td><td align="center">-33.2</td><td align="center">-86.3 &#x02013; 19.9</td><td align="center">0.22</td><td align="center">0.287</td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">Haplotype A*</td><td align="center">23.9</td><td align="center">-13.8 &#x02013; 61.6</td><td align="center">0.21</td><td align="center">7.0</td><td align="center">-26.5 &#x02013; 40.5</td><td align="center">0.68</td><td align="center">0.206</td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">Haplotype B</td><td align="center">8.9</td><td align="center">-33.2 &#x02013; 51.0</td><td align="center">0.68</td><td align="center">4.6</td><td align="center">-32.5 &#x02013; 41.7</td><td align="center">0.81</td><td align="center">0.601</td></tr></tbody></table><table-wrap-foot><p>Significant p values are depicted in bold</p><p>* for the recessive effect: B = 76.8 ml (95% CI: 8.0&#x02013;145.6), p = 0.03 (Doetinchem cohort) and B = 45.1 ml (95% CI: -15.5&#x02013;105.7) p = 0.14 (Vlagtwedde-Vlaardingen cohort); p = 0.01 in the pooled cohort analysis</p><p>Parameter estimate B (corresponding to the "per-allele" effect on the level of FEV<sub>1 </sub>in ml), its 95% Confidence Interval and p value are estimated for genetic variations in <italic>NFE2L2 </italic>and <italic>KEAP1 </italic>using Linear Mixed Effect model analysis on FEV<sub>1 </sub>level adjusted for genotypes (coded: 0 = homozygotes wild type, 1 = heterozygotes, 2 = homozygotes mutant) packyears smoked, sex, age, height and correlation of FEV<sub>1 </sub>measurements within subjects and cohort binary variable for the pooled cohorts analysis.</p><p>NFE2L2 = Nuclear Factor (Erythroid-derived 2)-Like 2</p><p>KEAP1 = Kelch-like ECH-associated protein-1</p><p>FEV<sub>1 </sub>= Forced Expiratory Volume in 1 second</p><p>CI = Confidence Interval</p></table-wrap-foot></table-wrap><p>Heterozygote subjects for rs2364723 SNP had a significantly lower FEV<sub>1 </sub>level as compared to homozygote wild type subjects (figure <xref ref-type="fig" rid="F2">2</xref>), while for the rs11085735 SNP all between-genotypes differences were significant in the pooled cohort analysis (figure <xref ref-type="fig" rid="F3">3</xref>).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Mean adjusted FEV<sub>1 </sub>level for heterozygote and homozygote mutant genotypes of the <italic>NFE2L2 </italic>rs2364723 SNP as compared to wild type</bold>. Mean adjusted effects (squares) and corresponding 95% Confidence Intervals (bars) are presented. *p &#x0003c; 0.05 as compared to wild type. <italic>NFE2L2 </italic>= <italic>Nuclear Factor Erythroid 2-Like 2</italic>. FEV<sub>1 </sub>= Forced Expiratory Volume in 1 second.</p></caption><graphic xlink:href="1465-9921-10-73-2"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Mean adjusted FEV<sub>1 </sub>level for heterozygote and homozygote mutant genotypes of the <italic>KEAP1 </italic>rs11085735 SNP as compared to wild type</bold>. Mean adjusted effects (squares) and corresponding 95% Confidence Intervals (bars) are presented. * p &#x0003c; 0.05 for homozygote mutant genotype as compared to wild type or heterozygotes. <sup>&#x02020; </sup>p &#x0003c; 0.05 for heterozygote genotype as compared to homozygote wild type or homozygote mutant. <sup>&#x02021; </sup>p &#x0003c; 0.05 for all between-genotype comparisons. <italic>KEAP1 = Kelch-like ECH-associated protein-1</italic>. FEV<sub>1 </sub>= Forced Expiratory Volume in 1 second</p></caption><graphic xlink:href="1465-9921-10-73-3"/></fig><p>Haplotype C in <italic>NFE2L2 </italic>was associated with higher FEV<sub>1 </sub>levels using an additive model in the pooled cohort analysis exclusively (table <xref ref-type="table" rid="T4">4</xref>). Haplotype A in <italic>KEAP1 </italic>was associated with higher FEV<sub>1 </sub>level in a recessive model in the pooled cohort analysis (table <xref ref-type="table" rid="T4">4</xref>). No additional consistent associations were observed for other SNPs or other genetic models (data not shown).</p><sec><title>Interaction between SNPs in NFE2L2 and KEAP1</title><p>There was no significant interaction between SNPs in <italic>KEAP1 </italic>and <italic>NFE2L2 </italic>(using combinations of dominant and/or additive effects) in relation to the level of FEV<sub>1 </sub>in the pooled cohort analysis (data not shown).</p></sec></sec><sec><title>Interaction between smoking and <italic>NFE2L2 </italic>and <italic>KEAP1 </italic>variations and level of FEV<sub>1</sub></title><p>We observed no significant interaction between ever/never smoking status and variations in <italic>NFE2L2 </italic>or <italic>KEAP1 </italic>in relation to the level of FEV<sub>1</sub>. Yet the effect of rs11085735 in <italic>KEAP1 </italic>was significant only in never smokers, while the effect of rs2364723 and haplotype C in <italic>NFE2L2 </italic>was significant only in ever smokers (table <xref ref-type="table" rid="T5">5</xref>). In the pooled cohort analysis we observed significant interactions between packyears smoked with two linked variations in <italic>KEAP1 </italic>i.e. rs1048290 (B<sub>INT </sub>= 1.9 ml/(packyear*allele number) SE<sub>INT </sub>= 0.9 p = 0.03) and haplotype B (B<sub>INT </sub>= 1.9 ml/(packyear*allele number) SE<sub>INT </sub>= 0.9 p = 0.04). In the single cohort analysis these interaction terms were not significant (p &#x0003e; 0.10 for both cohorts).</p><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Additive effects of <italic>NFE2L2 </italic>and <italic>KEAP1 </italic>SNPs on the level of FEV<sub>1 </sub>in never- and ever-smokers</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td></td><td align="center" colspan="6"><bold>Doetinchem cohort (n = 1,152)</bold><break/><italic>second survey</italic></td><td align="center" colspan="6"><bold>Vlagtwedde-Vlaardingen cohort (n = 1,390)</bold><break/><italic>last survey</italic></td></tr><tr><td></td><td></td><td colspan="12"><hr></hr></td></tr><tr><td align="left"><bold>Gene</bold></td><td align="left"><bold>Variation</bold></td><td align="center" colspan="3"><bold>Never smokers</bold></td><td align="center" colspan="3"><bold>Ever smokers</bold></td><td align="center" colspan="3"><bold>Never smokers</bold></td><td align="center" colspan="3"><bold>Ever smokers</bold></td></tr><tr><td></td><td></td><td colspan="12"><hr></hr></td></tr><tr><td></td><td></td><td align="center"><bold>B [ml]</bold></td><td align="center"><bold>SE</bold></td><td align="center"><bold>p</bold></td><td align="center"><bold>B [ml]</bold></td><td align="center"><bold>SE</bold></td><td align="center"><bold>p</bold></td><td align="center"><bold>B [ml]</bold></td><td align="center"><bold>SE</bold></td><td align="center"><bold>p</bold></td><td align="center"><bold>B [ml]</bold></td><td align="center"><bold>SE</bold></td><td align="center"><bold>p</bold></td></tr></thead><tbody><tr><td align="left"><italic>NFE2L2</italic></td><td align="left">rs6726395</td><td align="center">-33.1</td><td align="center">34.1</td><td align="center">0.33</td><td align="center">-3.4</td><td align="center">24.2</td><td align="center">0.89</td><td align="center">9.7</td><td align="center">28.3</td><td align="center">0.73</td><td align="center">6.4</td><td align="center">22.7</td><td align="center">0.78</td></tr><tr><td></td><td colspan="13"><hr></hr></td></tr><tr><td></td><td align="left">rs4243387</td><td align="center">15.5</td><td align="center">55.5</td><td align="center">0.78</td><td align="center">-1.2</td><td align="center">41.1</td><td align="center">0.98</td><td align="center">3.9</td><td align="center">56.0</td><td align="center">0.94</td><td align="center">12.8</td><td align="center">38.6</td><td align="center">0.74</td></tr><tr><td></td><td colspan="13"><hr></hr></td></tr><tr><td></td><td align="left">rs1806649</td><td align="center">-97.1</td><td align="center">37.7</td><td align="center">0.01</td><td align="center">-19.0</td><td align="center">28.4</td><td align="center">0.50</td><td align="center">40.6</td><td align="center">31.5</td><td align="center">0.20</td><td align="center">-13.1</td><td align="center">26.6</td><td align="center">0.62</td></tr><tr><td></td><td colspan="13"><hr></hr></td></tr><tr><td></td><td align="left">rs13001694</td><td align="center">-54.5</td><td align="center">34.7</td><td align="center">0.12</td><td align="center">-16.0</td><td align="center">24.5</td><td align="center">0.52</td><td align="center">13.5</td><td align="center">28.2</td><td align="center">0.63</td><td align="center">5.6</td><td align="center">23.3</td><td align="center">0.81</td></tr><tr><td></td><td colspan="13"><hr></hr></td></tr><tr><td></td><td align="left">rs2364723</td><td align="center">21.5</td><td align="center">37.3</td><td align="center">0.56</td><td align="center">-36.6</td><td align="center">26.8</td><td align="center"><bold>0.17</bold></td><td align="center">-3.2</td><td align="center">28.4</td><td align="center">0.91</td><td align="center">-36.2</td><td align="center">24.0</td><td align="center"><bold>0.13</bold></td></tr><tr><td></td><td colspan="13"><hr></hr></td></tr><tr><td></td><td align="left">Haplotype C</td><td align="center">3.5</td><td align="center">44.6</td><td align="center">0.94</td><td align="center">54.2</td><td align="center">31.3</td><td align="center"><bold>0.08</bold></td><td align="center">-22.9</td><td align="center">35.2</td><td align="center">0.52</td><td align="center">47.5</td><td align="center">30.5</td><td align="center"><bold>0.12</bold></td></tr><tr><td></td><td colspan="13"><hr></hr></td></tr><tr><td></td><td align="left">Haplotype D</td><td align="center">86.7</td><td align="center">59.1</td><td align="center">0.14</td><td align="center">19.5</td><td align="center">37.0</td><td align="center">0.60</td><td align="center">-40.3</td><td align="center">42.5</td><td align="center">0.34</td><td align="center">38.7</td><td align="center">37.1</td><td align="center">0.30</td></tr><tr><td colspan="14"><hr></hr></td></tr><tr><td align="left"><italic>KEAP1</italic></td><td align="left"><underline>rs1048290</underline></td><td align="center">-0.8</td><td align="center">35.3</td><td align="center">0.98</td><td align="center">17.0</td><td align="center">25.5</td><td align="center">0.51</td><td align="center">-21.8</td><td align="center">29.2</td><td align="center">0.46</td><td align="center">44.6</td><td align="center">24.6</td><td align="center">0.07</td></tr><tr><td></td><td colspan="13"><hr></hr></td></tr><tr><td></td><td align="left">rs11085735</td><td align="center">116.2</td><td align="center">75.8</td><td align="center"><bold>0.13</bold></td><td align="center">64.6</td><td align="center">50.4</td><td align="center">0.20</td><td align="center">112.2</td><td align="center">60.8</td><td align="center"><bold>0.07</bold></td><td align="center">23.5</td><td align="center">54.5</td><td align="center">0.67</td></tr><tr><td></td><td colspan="13"><hr></hr></td></tr><tr><td></td><td align="left">rs1048287</td><td align="center">-25.0</td><td align="center">53.8</td><td align="center">0.64</td><td align="center">-10.4</td><td align="center">38.7</td><td align="center">0.79</td><td align="center">-56.8</td><td align="center">44.0</td><td align="center">0.20</td><td align="center">5.1</td><td align="center">38.6</td><td align="center">0.90</td></tr><tr><td></td><td colspan="13"><hr></hr></td></tr><tr><td></td><td align="left">Haplotype A*</td><td align="center">25.8</td><td align="center">34.0</td><td align="center">0.45</td><td align="center">22.1</td><td align="center">24.9</td><td align="center">0.38</td><td align="center">4.8</td><td align="center">28.8</td><td align="center">0.87</td><td align="center">36.7</td><td align="center">23.8</td><td align="center">0.12</td></tr><tr><td></td><td colspan="13"><hr></hr></td></tr><tr><td></td><td align="left"><underline>Haplotype B</underline></td><td align="center">12.3</td><td align="center">38.3</td><td align="center">0.75</td><td align="center">2.3</td><td align="center">27.8</td><td align="center">0.93</td><td align="center">3.6</td><td align="center">30.7</td><td align="center">0.91</td><td align="center">46.3</td><td align="center">26.7</td><td align="center">0.08</td></tr></tbody></table><table-wrap-foot><p>P values depicted in bold indicate associations significant (p &#x0003c; 0.05) in the pooled cohort analysis within never- or ever-smokers.</p><p>*p &#x0003c; 0.05 for a positive recessive effect in ever and never smokers in the pooled cohort analysis (p &#x0003e; 0.05 for the analysis concerning separate cohorts)</p><p>None of the SNP in any model showed significantly different effect between never and ever smokers as tested with the pooled cohort linear regression analysis containing interaction term (binary variable reflecting smoking status) adjusted for height, sex, age, cohort and ever/never smoking status. Two underlined <italic>KEAP1 </italic>variations showed a significant interaction with packyears smoked in an additive model within ever-smokers in the pooled cohort analysis:</p><p>rs1048290: B<sub>INT </sub>= 1.9 ml/(packyear*number of alleles) SE<sub>INT </sub>= 0.9 p = 0.03</p><p>Haplotype B: B<sub>INT </sub>= 1.9 ml/(packyear*number of alleles) SE<sub>INT </sub>= 0.9 p = 0.04</p></table-wrap-foot></table-wrap></sec><sec><title>SNPs in <italic>NFE2L2 </italic>and <italic>KEAP1 </italic>and course of FEV<sub>1</sub></title><p>We did not observe any significant effect of SNPs in <italic>NFE2L2 </italic>and/or <italic>KEAP1 </italic>on the course of FEV<sub>1 </sub>in either of the cohorts nor in the pooled cohort analysis for any genetic model tested (see table <xref ref-type="table" rid="T6">6</xref> for additive effects).</p><table-wrap position="float" id="T6"><label>Table 6</label><caption><p>Additive effects of genetic variations in <italic>NFE2L2 </italic>and <italic>KEAP1 </italic>on the longitudinal course of FEV<sub>1</sub></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Gene</bold></td><td align="left"><bold>Variation</bold></td><td align="center" colspan="3"><bold>Doetinchem cohort</bold></td><td align="center" colspan="3"><bold>Vlagtwedde-Vlaardingen cohort</bold></td><td align="center"><bold>Pooled cohorts</bold></td></tr><tr><td></td><td></td><td colspan="7"><hr></hr></td></tr><tr><td></td><td></td><td align="center"><bold>B [ml/yr]</bold></td><td align="center"><bold>95% CI</bold></td><td align="center"><bold>p</bold></td><td align="center"><bold>B [ml/yr]</bold></td><td align="center"><bold>95% CI</bold></td><td align="center"><bold>p</bold></td><td align="center"><bold>p</bold></td></tr></thead><tbody><tr><td align="left"><italic>NFE2L2</italic></td><td align="left">rs6726395</td><td align="center">0.2</td><td align="center">-2.5 &#x02013; 2.9</td><td align="center">0.88</td><td align="center">0.1</td><td align="center">-1.5 &#x02013; 1.7</td><td align="center">0.90</td><td align="center">0.873</td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">rs4243387</td><td align="center">-1.2</td><td align="center">-5.6 &#x02013; 3.2</td><td align="center">0.60</td><td align="center">-1.9</td><td align="center">-4.8 &#x02013; 1.1</td><td align="center">0.21</td><td align="center">0.106</td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">rs1806649</td><td align="center">1.5</td><td align="center">-1.6 &#x02013; 4.5</td><td align="center">0.35</td><td align="center">1.0</td><td align="center">-1.0 &#x02013; 3.0</td><td align="center">0.31</td><td align="center">0.151</td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">rs13001694</td><td align="center">0.0</td><td align="center">-2.7 &#x02013; 2.7</td><td align="center">1.00</td><td align="center">0.7</td><td align="center">-1.0 &#x02013; 2.4</td><td align="center">0.40</td><td align="center">0.337</td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">rs2364723</td><td align="center">-0.3</td><td align="center">-3.2 &#x02013; 2.6</td><td align="center">0.84</td><td align="center">-0.6</td><td align="center">-2.3 &#x02013; 1.1</td><td align="center">0.50</td><td align="center">0.368</td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">Haplotype C</td><td align="center">-0.3</td><td align="center">-3.8 &#x02013; 3.1</td><td align="center">0.85</td><td align="center">0.9</td><td align="center">-1.3 &#x02013; 3.1</td><td align="center">0.40</td><td align="center">0.401</td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">Haplotype D</td><td align="center">-2.3</td><td align="center">-6.6 &#x02013; 2.0</td><td align="center">0.29</td><td align="center">0.0</td><td align="center">-2.6 &#x02013; 2.5</td><td align="center">0.98</td><td align="center">0.627</td></tr><tr><td colspan="9"><hr></hr></td></tr><tr><td align="left"><italic>KEAP1</italic></td><td align="left">rs1048290</td><td align="center">-2.0</td><td align="center">-4.7 &#x02013; 0.8</td><td align="center">0.16</td><td align="center">1.0</td><td align="center">-0.8 &#x02013; 2.8</td><td align="center">0.28</td><td align="center">0.907</td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">rs11085735</td><td align="center">3.6</td><td align="center">-2.1 &#x02013; 9.4</td><td align="center">0.22</td><td align="center">-0.7</td><td align="center">-4.7 &#x02013; 3.3</td><td align="center">0.72</td><td align="center">0.774</td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">rs1048287</td><td align="center">-1.8</td><td align="center">-5.9 &#x02013; 2.4</td><td align="center">0.41</td><td align="center">-0.4</td><td align="center">-3.1 &#x02013; 2.4</td><td align="center">0.80</td><td align="center">0.614</td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">Haplotype A</td><td align="center">-1.3</td><td align="center">-4.0 &#x02013; 1.4</td><td align="center">0.35</td><td align="center">0.8</td><td align="center">-1.0 &#x02013; 2.5</td><td align="center">0.38</td><td align="center">0.817</td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td></td><td align="left">Haplotype B</td><td align="center">-1.6</td><td align="center">-4.6 &#x02013; 1.4</td><td align="center">0.30</td><td align="center">1.5</td><td align="center">-0.5 &#x02013; 3.4</td><td align="center">0.14</td><td align="center">0.573</td></tr></tbody></table><table-wrap-foot><p>Parameter estimate B (corresponding to the "per-allele" effect on the change in FEV<sub>1 </sub>in ml/yr), its 95% Confidence Interval and p value are estimated for genetic variations in <italic>NFE2L2 </italic>and <italic>KEAP1 </italic>using Linear Mixed Effect model analysis on FEV<sub>1 </sub>level adjusted for genotypes (coded: 0 = homozygotes wild type, 1 = heterozygotes, 2 = homozygotes mutant), age at entry, sex, packyears smoked, FEV<sub>1 </sub>level at baseline (and their interaction with time) and correlation of lung function measurements within subjects (random factor assigned to the intercept and time) and cohort binary variable for the pooled cohorts analysis.</p><p>NFE2L2 = Nuclear Factor (Erythroid-derived 2)-Like 2 </p><p>KEAP1 = Kelch-like ECH-associated protein-1 </p><p>FEV<sub>1 </sub>= Forced Expiratory Volume in 1 second</p><p>CI = Confidence Interval</p></table-wrap-foot></table-wrap></sec></sec><sec><title>Discussion</title><p>The current study shows that polymorphisms in antioxidant transcription factor <italic>NFE2L2 </italic>and its repressor <italic>KEAP1 </italic>affect the level of FEV<sub>1 </sub>in the general population.</p><p>NFE2L2 is required for the transcription initiation of many antioxidant-related genes including candidate genes for lung excess function loss and COPD development such as <italic>Heme Oxygenase 1 </italic>and <italic>Glutamate Cysteine Ligase </italic>[<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. Moreover, murine models have shown that the <italic>Nfe2l2 </italic>depletion <italic>in vivo </italic>results in elastase- [<xref ref-type="bibr" rid="B17">17</xref>] and cigarette smoke-induced [<xref ref-type="bibr" rid="B18">18</xref>] emphysema development. Thus a functional genetic impairment concerning <italic>NFE2L2 </italic>and/or its cytosolic repressor <italic>KEAP1 </italic>would likely result in detrimental consequences <italic>in vivo</italic>.</p><p>It has been shown that lung function is genetically determined [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>], however so far only low-prevalent polymorphisms have been consistently associated with COPD development across independent studies, i.e. the Glu342Lys substitution in <italic>SERPINA1 </italic>(frequency 1%&#x02013;3% in Caucasians) that leads to a1-antitrypsin deficiency [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B8">8</xref>] and the Arg213Gly substitution in <italic>Superoxide Dismutase 3 </italic>(frequency 1%&#x02013;2% in Caucasians) [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>], suggesting that low-prevalent SNPs are important contributors to COPD development. Detection of the effect provided by such low prevalent SNPs often requires large sample sizes, even when the effect size is substantial. Similarly, small genetic effects for highly prevalent variations, such as those genotyped in the current study, need to be assessed in large sample sizes. Therefore, we used all available FEV<sub>1 </sub>measurements in both cohorts, in order to achieve the highest possible statistical power. Moreover, we additionally performed analyses on the pooled cohorts including over 2,500 subjects with over 11,000 FEV<sub>1 </sub>measurements.</p><p>In our opinion the most convincing association shown in the current study was that the rs11085735 SNP in <italic>KEAP1 </italic>significantly associated with higher FEV<sub>1 </sub>levels in the pooled cohort as well as in both cohorts analyzed separately, yet using different genetic models. This SNP is located in the intron 3 of <italic>KEAP1</italic>, relatively close (73 bp) to the exon 3 of this gene, and thus it might have functional consequences e.g. via affecting <italic>KEAP1 </italic>mRNA splicing. Haplotype A in <italic>KEAP1 </italic>was associated with higher FEV<sub>1 </sub>level in the Doetinchem cohort and in the pooled cohort analysis using a recessive model only. Since this haplotype does not tag any SNP that was investigated in the current study, it may be in linkage disequilibrium with another functional SNP that is either not known yet or is located outside the region that was selected for tagging.</p><p>SNP rs2364723 and haplotype C in <italic>NFE2L2 </italic>were associated with the level of FEV<sub>1 </sub>in the pooled cohort analysis, as caused by a similar though not significant trends present in both cohorts. SNP rs2364723 is in almost complete LD with the recently described promoter polymorphisms i.e. G(-686)A (rs35652124) and CCG Trinucleotide repeat (figure <xref ref-type="fig" rid="F1">1</xref>) [<xref ref-type="bibr" rid="B22">22</xref>], implicating a role in the regulation of <italic>NFE2L2 </italic>transcription. We found no evidence for an association of another previously identified functional <italic>NFE2L2 </italic>SNP (i.e. C(-650)A (rs6721961) tagged by us with rs4243387 SNP) [<xref ref-type="bibr" rid="B23">23</xref>].</p><p>None of the analyzed genetic variations showed a significantly different effect on the level of FEV<sub>1 </sub>between never and ever smokers, yet the effects provided by <italic>NFE2L2 </italic>rs2364723 SNP and haplotype C were more prominent in ever smokers while the effect of <italic>KEAP1 </italic>rs11085735 SNP was significant in never smokers exclusively. Interestingly another variation in <italic>KEAP1 </italic>(i.e. rs1048290 linked with haplotype B) showed a protective effect on the level on FEV<sub>1 </sub>in interaction with packyears smoked within ever smokers. The observed association of the level of FEV<sub>1 </sub>and the interaction between rs1048290 SNP and smoking can be somewhat weakened by a deviation from HWE observed for this SNP in one of the cohorts studied. Since the common cause of such deviation is a genotyping error, we have genotyped another, completely correlated, rs9676881 SNP, which also showed significant deviation from HWE. This suggests that genotyping error was not a cause of the observed deviation from HWE. Significant results obtained in the analysis stratified by smoking status (ever and never smokers), or in the gene by packyears interaction analysis did not reach significance in either of the cohorts analyzed separately. Since this could be due to insufficient power provided by single cohorts, subsequent studies are warranted.</p><p>Using publicly available data on the British 1958 Birth cohort [<xref ref-type="bibr" rid="B35">35</xref>], we checked whether our results on the significant association of SNPs with the level of FEV<sub>1 </sub>could be replicated in this independent population. The additive effects provided by. rs11085735 in <italic>KEAP1 </italic>and rs2364723 in <italic>NFE2L2 </italic>were not significant, p values being 0.11 and 0.59&#x02013;0.70 (depending on the genotyping method) respectively. However, both associations were in the same direction as found in our two Dutch cohorts, i.e. positive for rs11085735 in <italic>KEAP1 </italic>(B = 52.7 ml/allele, 95% Confidence Interval (CI) = -12.6 &#x02013; 118.0) and negative for rs2364723 in <italic>NFE2L2 </italic>(B = -7.3 ml/allele, 95% CI = -44.3 &#x02013; 29.6, representing higher p value). A subsequent meta-analysis of the Doetinchem, Vlagtwedde-Vlaardingen and British 1958 Birth cohorts showed a higher significant protective effect of the <italic>KEAP1 </italic>SNP on the level of FEV<sub>1 </sub>(p = 0.0008) as compared to the pooled analysis in the two Dutch cohorts (p = 0.003, table <xref ref-type="table" rid="T4">4</xref>). The p value of the additive and detrimental effect of the rs2364723 SNP was significant as well (0.036&#x02013;0.046, depending on the genotyping technology in the British 1958 Birth Cohort), yet higher than the p value provided by the pooled analysis in the two Dutch cohorts (i.e. p = 0.026, table <xref ref-type="table" rid="T4">4</xref>).</p></sec><sec><title>Conclusion</title><p>Our study performed in two independent Dutch cohorts shows that genetic variations in <italic>KEAP1 </italic>and <italic>NFE2L2 </italic>affect the level, but not the longitudinal course of FEV<sub>1 </sub>in the general population. Therefore, it remains for future considerations whether these SNPs play a role in the development or growth of the lung. Given the importance of both genes in the regulation of oxidative stress in the lung, further studies focusing on the <italic>NFE2L2-KEAP1 </italic>pathway are warranted.</p></sec><sec><title>Competing interests</title><p>MS has no conflict of interest to disclose. DSP has no conflict of interest to disclose. JMAB has no conflict of interest to disclose. GvdS has no conflict of interest to disclose. JPS has no conflict of interest to disclose. HAS has no conflict of interest to disclose. HMB has no conflict of interest to disclose.</p></sec><sec><title>Authors' contributions</title><p>MS wrote the manuscript. MS, JPS, and HMB analyzed the data. HAS and JMAB designed the Doetinchem cohort study and managed the data. JPS designed the Vlagtwedde-Vlaardingen cohort study and managed the data. GvdS participated in the genotyping process. MS, JPS, MB, JMAB, HAS, and DS interpreted the data. All authors proposed corrections and approved the final version of the manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>SNP-selection and NFE2L2 genotyping</bold></p></caption><media xlink:href="1465-9921-10-73-S1.pdf" mimetype="application" mime-subtype="pdf"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>The authors thank the epidemiologists and fieldworkers of the Municipal Health Services in Doetinchem for their important contribution to the data collection of the Doetinchem Study as well as Jaap Seidell, Monique Verschuren, Bas Bueno-de Mesquita from the National Institute of Public Health in Bilthoven for conducting the study and Anneke Blokstra and Petra Vissink for the logistic and data management. Last but not least, the authors thank the participants of the Doetinchem and Vlagtwedde/Vlaardingen studies for their loyal participation every survey. The authors thank the staff of the genotyping unit of the Centre for Medical Biomics, particularly Elvira Oosterom, Marcel Bruinenberg and Mathieu Platteel for their help in genotyping of the <italic>NFE2L2 </italic>Trinucleotide Repeat. We acknowledge use of genotype data from the British 1958 Birth Cohort DNA collection, funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/02.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="other"><article-title>From the World Health Reports 2002 and 2003 (World Health Organisation)</article-title><ext-link ext-link-type="uri" xlink:href="http://www.who.int/whr/previous/en/index.html"/></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kueppers</surname><given-names>F</given-names></name><name><surname>Miller</surname><given-names>RD</given-names></name><name><surname>Gordon</surname><given-names>H</given-names></name><name><surname>Hepper</surname><given-names>NG</given-names></name><name><surname>Offord</surname><given-names>K</given-names></name></person-group><article-title>Familial prevalence of chronic obstructive pulmonary disease in a matched pair study</article-title><source>Am J Med</source><year>1977</year><volume>63</volume><fpage>336</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">302643</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Redline</surname><given-names>S</given-names></name><name><surname>Tishler</surname><given-names>PV</given-names></name><name><surname>Rosner</surname><given-names>B</given-names></name><name><surname>Lewitter</surname><given-names>FI</given-names></name><name><surname>Vandenburgh</surname><given-names>M</given-names></name><name><surname>Weiss</surname><given-names>ST</given-names></name><name><surname>Speizer</surname><given-names>FE</given-names></name></person-group><article-title>Genotypic and phenotypic similarities in pulmonary function among family members of adult monozygotic and dizygotic twins</article-title><source>Am J Epidemiol</source><year>1989</year><volume>129</volume><fpage>827</fpage><lpage>836</lpage><pub-id pub-id-type="pmid">2923128</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>EK</given-names></name></person-group><article-title>Progress in chronic obstructive pulmonary disease genetics</article-title><source>Proc Am Thorac Soc</source><year>2006</year><volume>3</volume><fpage>405</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">16799082</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hersh</surname><given-names>CP</given-names></name><name><surname>DeMeo</surname><given-names>DL</given-names></name><name><surname>Lange</surname><given-names>C</given-names></name><name><surname>Litonjua</surname><given-names>AA</given-names></name><name><surname>Reilly</surname><given-names>JJ</given-names></name><name><surname>Kwiatkowski</surname><given-names>D</given-names></name><name><surname>Laird</surname><given-names>N</given-names></name><name><surname>Sylvia</surname><given-names>JS</given-names></name><name><surname>Sparrow</surname><given-names>D</given-names></name><name><surname>Speizer</surname><given-names>FE</given-names></name><name><surname>Weiss</surname><given-names>ST</given-names></name><name><surname>Silverman</surname><given-names>EK</given-names></name></person-group><article-title>Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations</article-title><source>Am J Respir Cell Mol Biol</source><year>2005</year><volume>33</volume><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">15817713</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><article-title>Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group</article-title><source>Am J Respir Crit Care Med</source><year>1998</year><volume>158</volume><fpage>49</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">9655706</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DeMeo</surname><given-names>DL</given-names></name><name><surname>Silverman</surname><given-names>EK</given-names></name></person-group><article-title>Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk</article-title><source>Thorax</source><year>2004</year><volume>59</volume><fpage>259</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">14985567</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seersholm</surname><given-names>N</given-names></name><name><surname>Kok-Jensen</surname><given-names>A</given-names></name><name><surname>Dirksen</surname><given-names>A</given-names></name></person-group><article-title>Decline in FEV1 among patients with severe hereditary alpha 1-antitrypsin deficiency type PiZ</article-title><source>Am J Respir Crit Care Med</source><year>1995</year><volume>152</volume><fpage>1922</fpage><lpage>1925</lpage><pub-id pub-id-type="pmid">8520756</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Juul</surname><given-names>K</given-names></name><name><surname>Tybjaerg-Hansen</surname><given-names>A</given-names></name><name><surname>Marklund</surname><given-names>S</given-names></name><name><surname>Lange</surname><given-names>P</given-names></name><name><surname>Nordestgaard</surname><given-names>BG</given-names></name></person-group><article-title>Genetically increased antioxidative protection and decreased chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2006</year><volume>173</volume><fpage>858</fpage><lpage>864</lpage><pub-id pub-id-type="pmid">16399992</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>RP</given-names></name><name><surname>Hopkins</surname><given-names>R</given-names></name><name><surname>Black</surname><given-names>PN</given-names></name><name><surname>Eddy</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Gamble</surname><given-names>GD</given-names></name><name><surname>Mills</surname><given-names>GD</given-names></name><name><surname>Garrett</surname><given-names>JE</given-names></name><name><surname>Eaton</surname><given-names>TE</given-names></name><name><surname>Rees</surname><given-names>MI</given-names></name></person-group><article-title>Functional variants of antioxidant genes in smokers with COPD and in those with normal lung function</article-title><source>Thorax</source><year>2006</year><volume>61</volume><fpage>394</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">16467073</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guenegou</surname><given-names>A</given-names></name><name><surname>Leynaert</surname><given-names>B</given-names></name><name><surname>Benessiano</surname><given-names>J</given-names></name><name><surname>Pin</surname><given-names>I</given-names></name><name><surname>Demoly</surname><given-names>P</given-names></name><name><surname>Neukirch</surname><given-names>F</given-names></name><name><surname>Boczkowski</surname><given-names>J</given-names></name><name><surname>Aubier</surname><given-names>M</given-names></name></person-group><article-title>Association of lung function decline with the heme oxygenase-1 gene promoter microsatellite polymorphism in a general population sample. Results from the European Community Respiratory Health Survey (ECRHS), France</article-title><source>J Med Genet</source><year>2006</year><volume>43</volume><fpage>e43</fpage><pub-id pub-id-type="pmid">16882737</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adair-Kirk</surname><given-names>TL</given-names></name><name><surname>Atkinson</surname><given-names>JJ</given-names></name><name><surname>Griffin</surname><given-names>GL</given-names></name><name><surname>Watson</surname><given-names>MA</given-names></name><name><surname>Kelley</surname><given-names>DG</given-names></name><name><surname>DeMello</surname><given-names>D</given-names></name><name><surname>Senior</surname><given-names>RM</given-names></name><name><surname>Betsuyaku</surname><given-names>T</given-names></name></person-group><article-title>Distal airways in mice exposed to cigarette smoke: Nrf2-regulated genes are increased in Clara cells</article-title><source>Am J Respir Cell Mol Biol</source><year>2008</year><volume>39</volume><fpage>400</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">18441282</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pierrou</surname><given-names>S</given-names></name><name><surname>Broberg</surname><given-names>P</given-names></name><name><surname>O'Donnell</surname><given-names>RA</given-names></name><name><surname>Pawlowski</surname><given-names>K</given-names></name><name><surname>Virtala</surname><given-names>R</given-names></name><name><surname>Lindqvist</surname><given-names>E</given-names></name><name><surname>Richter</surname><given-names>A</given-names></name><name><surname>Wilson</surname><given-names>SJ</given-names></name><name><surname>Angco</surname><given-names>G</given-names></name><name><surname>Moller</surname><given-names>S</given-names></name><name><surname>Bergstrand</surname><given-names>H</given-names></name><name><surname>Koopmann</surname><given-names>W</given-names></name><name><surname>Wieslander</surname><given-names>E</given-names></name><name><surname>Str&#x000f6;mstedt</surname><given-names>PE</given-names></name><name><surname>Holgate</surname><given-names>ST</given-names></name><name><surname>Davies</surname><given-names>DE</given-names></name><name><surname>Lund</surname><given-names>J</given-names></name><name><surname>Djukanovic</surname><given-names>R</given-names></name></person-group><article-title>Expression of genes involved in oxidative stress responses in airway epithelial cells of smokers with chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2007</year><volume>175</volume><fpage>577</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">17158281</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>DA</given-names></name><name><surname>Stein</surname><given-names>TD</given-names></name><name><surname>Kraft</surname><given-names>AD</given-names></name><name><surname>Calkins</surname><given-names>MJ</given-names></name><name><surname>Jakel</surname><given-names>RJ</given-names></name><name><surname>Johnson</surname><given-names>JA</given-names></name></person-group><article-title>Nrf2, a multi-organ protector?</article-title><source>FASEB J</source><year>2005</year><volume>19</volume><fpage>1061</fpage><lpage>1066</lpage><pub-id pub-id-type="pmid">15985529</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>HY</given-names></name><name><surname>Reddy</surname><given-names>SP</given-names></name><name><surname>Kleeberger</surname><given-names>SR</given-names></name></person-group><article-title>Nrf2 defends the lung from oxidative stress</article-title><source>Antioxid Redox Signal</source><year>2006</year><volume>8</volume><fpage>76</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">16487040</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>A</given-names></name><name><surname>Ohta</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name></person-group><article-title>Unique function of the Nrf2-Keap1 pathway in the inducible expression of antioxidant and detoxifying enzymes</article-title><source>Methods Enzymol</source><year>2004</year><volume>378</volume><fpage>273</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">15038975</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishii</surname><given-names>Y</given-names></name><name><surname>Itoh</surname><given-names>K</given-names></name><name><surname>Morishima</surname><given-names>Y</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Kiwamoto</surname><given-names>T</given-names></name><name><surname>Iizuka</surname><given-names>T</given-names></name><name><surname>Hegab</surname><given-names>AE</given-names></name><name><surname>Hosoya</surname><given-names>T</given-names></name><name><surname>Nomura</surname><given-names>A</given-names></name><name><surname>Sakamoto</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Sekizawa</surname><given-names>K</given-names></name></person-group><article-title>Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema</article-title><source>J Immunol</source><year>2005</year><volume>175</volume><fpage>6968</fpage><lpage>6975</lpage><pub-id pub-id-type="pmid">16272357</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iizuka</surname><given-names>T</given-names></name><name><surname>Ishii</surname><given-names>Y</given-names></name><name><surname>Itoh</surname><given-names>K</given-names></name><name><surname>Kiwamoto</surname><given-names>T</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Matsuno</surname><given-names>Y</given-names></name><name><surname>Morishima</surname><given-names>Y</given-names></name><name><surname>Hegab</surname><given-names>AE</given-names></name><name><surname>Homma</surname><given-names>S</given-names></name><name><surname>Nomura</surname><given-names>A</given-names></name><name><surname>Sakamoto</surname><given-names>T</given-names></name><name><surname>Shimura</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>A</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Sekizawa</surname><given-names>K</given-names></name></person-group><article-title>Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema</article-title><source>Genes Cells</source><year>2005</year><volume>10</volume><fpage>1113</fpage><lpage>1125</lpage><pub-id pub-id-type="pmid">16324149</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goven</surname><given-names>D</given-names></name><name><surname>Boutten</surname><given-names>A</given-names></name><name><surname>Lecon-Malas</surname><given-names>V</given-names></name><name><surname>Marchal-Somme</surname><given-names>J</given-names></name><name><surname>Amara</surname><given-names>N</given-names></name><name><surname>Crestani</surname><given-names>B</given-names></name><name><surname>Fournier</surname><given-names>M</given-names></name><name><surname>Leseche</surname><given-names>G</given-names></name><name><surname>Soler</surname><given-names>P</given-names></name><name><surname>Boczkowski</surname><given-names>J</given-names></name><name><surname>Bonay</surname><given-names>M</given-names></name></person-group><article-title>Altered Nrf2/Keap1-Bach1 equilibrium in pulmonary emphysema</article-title><source>Thorax</source><year>2008</year><volume>63</volume><fpage>916</fpage><lpage>924</lpage><pub-id pub-id-type="pmid">18559366</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Betsuyaku</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Nagai</surname><given-names>K</given-names></name><name><surname>Nasuhara</surname><given-names>Y</given-names></name><name><surname>Kaga</surname><given-names>K</given-names></name><name><surname>Kondo</surname><given-names>S</given-names></name><name><surname>Nishimura</surname><given-names>M</given-names></name></person-group><article-title>Downregulated NF-E2-related Factor 2 in Pulmonary Macrophages of Aged Smokers and COPD Patients</article-title><source>Am J Respir Cell Mol Biol</source><year>2008</year><volume>39</volume><fpage>673</fpage><lpage>682</lpage><pub-id pub-id-type="pmid">18566336</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malhotra</surname><given-names>D</given-names></name><name><surname>Thimmulappa</surname><given-names>R</given-names></name><name><surname>Navas-Acien</surname><given-names>A</given-names></name><name><surname>Sandford</surname><given-names>A</given-names></name><name><surname>Elliott</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Zhuang</surname><given-names>X</given-names></name><name><surname>Hogg</surname><given-names>J</given-names></name><name><surname>Pare</surname><given-names>P</given-names></name><name><surname>Tuder</surname><given-names>RM</given-names></name><name><surname>Biswal</surname><given-names>S</given-names></name></person-group><article-title>Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1</article-title><source>Am J Respir Crit Care Med</source><year>2008</year><volume>178</volume><fpage>592</fpage><lpage>604</lpage><pub-id pub-id-type="pmid">18556627</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Yoh</surname><given-names>K</given-names></name><name><surname>Kobayashi</surname><given-names>A</given-names></name><name><surname>Ishii</surname><given-names>Y</given-names></name><name><surname>Kure</surname><given-names>S</given-names></name><name><surname>Koyama</surname><given-names>A</given-names></name><name><surname>Sakamoto</surname><given-names>T</given-names></name><name><surname>Sekizawa</surname><given-names>K</given-names></name><name><surname>Motohashi</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name></person-group><article-title>Identification of polymorphisms in the promoter region of the human NRF2 gene</article-title><source>Biochem Biophys Res Commun</source><year>2004</year><volume>321</volume><fpage>72</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">15358217</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marzec</surname><given-names>JM</given-names></name><name><surname>Christie</surname><given-names>JD</given-names></name><name><surname>Reddy</surname><given-names>SP</given-names></name><name><surname>Jedlicka</surname><given-names>AE</given-names></name><name><surname>Vuong</surname><given-names>H</given-names></name><name><surname>Lanken</surname><given-names>PN</given-names></name><name><surname>Aplenc</surname><given-names>R</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Cho</surname><given-names>HY</given-names></name><name><surname>Kleeberger</surname><given-names>SR</given-names></name></person-group><article-title>Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury</article-title><source>FASEB J</source><year>2007</year><volume>21</volume><fpage>2237</fpage><lpage>2246</lpage><pub-id pub-id-type="pmid">17384144</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anto</surname><given-names>JM</given-names></name><name><surname>Vermeire</surname><given-names>P</given-names></name><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Sunyer</surname><given-names>J</given-names></name></person-group><article-title>Epidemiology of chronic obstructive pulmonary disease</article-title><source>Eur Respir J</source><year>2001</year><volume>17</volume><fpage>982</fpage><lpage>994</lpage><pub-id pub-id-type="pmid">11488336</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verschuren</surname><given-names>W</given-names></name><name><surname>Blokstra</surname><given-names>A</given-names></name><name><surname>Picavet</surname><given-names>H</given-names></name><name><surname>Smit</surname><given-names>H</given-names></name></person-group><article-title>Cohort Profile: The Doetinchem Cohort Study</article-title><source>Int J Epidemiol</source><year>2008</year><volume>37</volume><fpage>1236</fpage><lpage>1241</lpage><pub-id pub-id-type="pmid">18238821</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grievink</surname><given-names>L</given-names></name><name><surname>Smit</surname><given-names>HA</given-names></name><name><surname>Ocke</surname><given-names>MC</given-names></name><name><surname>van't Veer</surname><given-names>P</given-names></name><name><surname>Kromhout</surname><given-names>D</given-names></name></person-group><article-title>Dietary intake of antioxidant (pro)-vitamins, respiratory symptoms and pulmonary function: the MORGEN study</article-title><source>Thorax</source><year>1998</year><volume>53</volume><fpage>166</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">9659349</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siedlinski</surname><given-names>M</given-names></name><name><surname>Postma</surname><given-names>DS</given-names></name><name><surname>van Diemen</surname><given-names>CC</given-names></name><name><surname>Blokstra</surname><given-names>A</given-names></name><name><surname>Smit</surname><given-names>HA</given-names></name><name><surname>Boezen</surname><given-names>HM</given-names></name></person-group><article-title>Lung function loss, smoking, vitamin C intake and polymorphisms of the glutamate-cysteine ligase genes</article-title><source>Am J Respir Crit Care Med</source><year>2008</year><volume>178</volume><fpage>13</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">18420959</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quanjer</surname><given-names>PH</given-names></name><name><surname>Tammeling</surname><given-names>GJ</given-names></name><name><surname>Cotes</surname><given-names>JE</given-names></name><name><surname>Pedersen</surname><given-names>OF</given-names></name><name><surname>Peslin</surname><given-names>R</given-names></name><name><surname>Yernault</surname><given-names>JC</given-names></name></person-group><article-title>Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society</article-title><source>Eur Respir J Suppl</source><year>1993</year><volume>16</volume><fpage>5</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">8499054</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Diemen</surname><given-names>CC</given-names></name><name><surname>Postma</surname><given-names>DS</given-names></name><name><surname>Vonk</surname><given-names>JM</given-names></name><name><surname>Bruinenberg</surname><given-names>M</given-names></name><name><surname>Schouten</surname><given-names>JP</given-names></name><name><surname>Boezen</surname><given-names>HM</given-names></name></person-group><article-title>A disintegrin and metalloprotease 33 polymorphisms and lung function decline in the general population</article-title><source>Am J Respir Crit Care Med</source><year>2005</year><volume>172</volume><fpage>329</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">15879414</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><article-title>Haploview: analysis and visualization of LD and haplotype maps</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>263</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">15297300</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>NJ</given-names></name><name><surname>Donnelly</surname><given-names>P</given-names></name></person-group><article-title>A new statistical method for haplotype reconstruction from population data</article-title><source>Am J Hum Genet</source><year>2001</year><volume>68</volume><fpage>978</fpage><lpage>989</lpage><pub-id pub-id-type="pmid">11254454</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname><given-names>M</given-names></name><name><surname>Scheet</surname><given-names>P</given-names></name></person-group><article-title>Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation</article-title><source>Am J Hum Genet</source><year>2005</year><volume>76</volume><fpage>449</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">15700229</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bax</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>LM</given-names></name><name><surname>Ikeda</surname><given-names>N</given-names></name><name><surname>Tsuruta</surname><given-names>H</given-names></name><name><surname>Moons</surname><given-names>KG</given-names></name></person-group><article-title>Development and validation of MIX: comprehensive free software for meta-analysis of causal research data</article-title><source>BMC Med Res Methodol</source><year>2006</year><volume>6</volume><fpage>50</fpage><pub-id pub-id-type="pmid">17038197</pub-id></citation></ref><ref id="B34"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Bax</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>LM</given-names></name><name><surname>Ikeda</surname><given-names>N</given-names></name><name><surname>Tsuruta</surname><given-names>H</given-names></name><name><surname>Moons</surname><given-names>KGM</given-names></name></person-group><article-title>MIX: comprehensive free software for meta-analysis of causal research data. Version 1.7</article-title></citation></ref><ref id="B35"><citation citation-type="other"><article-title>Genetic information from the British 1958 Birth Cohort</article-title><ext-link ext-link-type="uri" xlink:href="http://www.b58cgene.sgul.ac.uk/"/></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siedlinski</surname><given-names>M</given-names></name><name><surname>van Diemen</surname><given-names>CC</given-names></name><name><surname>Postma</surname><given-names>DS</given-names></name><name><surname>Boezen</surname><given-names>HM</given-names></name></person-group><article-title>Heme oxygenase 1 variations and lung function decline in smokers: proof of replication</article-title><source>J Med Genet</source><year>2008</year><volume>45</volume><fpage>400</fpage><pub-id pub-id-type="pmid">18519631</pub-id></citation></ref></ref-list></back></article> 